- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cipla to soon unveil COVID drug Ciplenza for Rs 68
Cipla said it will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet.
Mumbai: Drug maker Cipla Ltd. on Friday said it has received regulatory approval from Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza to treat mild to moderate Covid-19 patients.
Favipiravir is an off patent, oral antiviral drug that has been shown to hasten clinical recovery in Covid-19 patients with mild to moderate symptoms.
The accelerated approval for manufacturing and marketing of the drug is aimed at meeting the urgent and unmet medical need for Covid-19 treatment options in the country through restricted emergency use.
Cipla said it will commercially launch Ciplenza in the first week of August priced at Rs 68 per tablet.
The price of Favipiravir has become a matter of great concern in the country as Glenmark Pharmaceuticals faced flak after it initially launched its Favipiravir drug under the brand name FabiFlu at Rs 103 per tablet.
Subsequently on July 13, Glenmark reduced the price of FabiFlu to Rs 75 per tablet.
Cipla said to ensure fair and equitable distribution of the drug, supplies will be undertaken predominantly through hospital channels and via open channels, prioritised for regions with a high burden of Covid-19 cases.
The drug has been jointly developed by Cipla and CSIR-Indian Institute of Chemical Technology (IICT).
As part of this partnership, CSIR-IICT has successfully developed a convenient and cost-effective synthetic process for Favipiravir.
The entire process and active pharmaceutical ingredient (API) of the drug has been transferred to Cipla to manufacture and market the drug at scale.
Towards providing drugs for coronavirus patients in India, CSIR late in April said it had identified top 25 drugs/drug candidates for repurposing.
Among these top 25 drugs, Favipiravir, a broad-spectrum inhibitor of viral RNA polymerase emerged as one of the most promising drugs.
Favipiravir was developed by Fujifilm Toyama Chemical Ltd., and is used for the treatment of common influenza in some markets.
Also Read: DCGI Nod To Two Cheaper Favipiravir Versions Priced At Rs 59, Rs 39 Per Tablets
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.